Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval marks the eighth indication for docetaxel in five different tumor types.
You may also be interested in...
Sanofi’s Taxotere Gets Priority Review For Head And Neck Cancer Claim
Approval would place the taxane in more direct competition with ImClone/Bristol’s Erbitux.
Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer
ImClone/Bristol will discuss potential for submitting an sBLA for the indication with FDA.
Erbitux Pricing Could Be Modified With Longer Treatment Cycles
Cetuximab was approved March 1 for treatment of advanced head and neck cancer.